Anti-PD-1 antibodies / PD-1 inhibitors + Chemotherapy (CT) & Esophageal adenocarcinoma (EAC)

Outcome

Compared with the chemotherapy group, the OS (HR = 0.70; P < 0.01) and PFS (HR = 0.62; P < 0.01) were significantly longer and the objective response rate (OR = 2.07; P < 0.01) was significantly higher in the PD-1 inhibitor plus chemotherapy group. An OS benefit was observed in patients regardless of histology or programmed cell death 1 ligand 1 combined positive score.
Lu et al. 2022a J Immunotherapy 45: 243

Safety

In safety analyses, PD-1 inhibitor plus chemotherapy had a significantly higher incidence of TRAEs (OR = 1.85; P < 0.01), but there was no significant difference in grade 3 or higher TRAEs (OR = 1.24; P = 0.05).
[Lu et al. 2022a J Immunotherapy 45: 243](brain://aK5g9Grp5EK9eE…